NEW YORK (GenomeWeb news) – ARUP Laboratories, a diagnostic testing services provider in Salt Lake City, has licensed a biomarker from Epigenomics for use in developing an early detection test for colorectal cancer.
Berlin, Germany-based Epigenomics said today that ARUP has signed a non-exclusive license to use the DNA methylated Septin 9 gene to develop a test for colorectal cancer from a patient's blood sample.
The company said that it has demonstrated that methylated DNA of the Septin 9 gene indicates colorectal cancer in the early stages.
"Having a simple blood test that can detect colorectal cancer will be a major step in the fight against this dreadful disease, which is often curable when caught in the early stages," ARUP's executive VP of Health Policy, External Affairs and Corporate Communication, Ronald Weiss, said in a statement.
"All too often, patients fail to undergo a colonoscopy or conduct other types of colorectal cancer screenings because they find these methods invasive, unpleasant or costly. A blood test for detecting colorectal cancer, will be a convenient option that complements other screening methods," Weiss added.
ARUP is the second lab partner to use the biomarker in a lab-developed test, following Quest Diagnostics. Abbott Molecular and Sysmex also have obtained rights to commercialize diagnostic tests based on the technology, Epigenomics CEO Geert Nygaard noted.
Financial terms of the agreement were not released.